Abstract

This is a competing continuation application for the Multidisciplinary Cancer Research Training Program (MCRTP) at the University of Utah. The MCRTP trains pre and postdoctoral scientists who will initiate independent careers in cancer research. Trainees acquire a deep understanding of clinical and mechanistic aspects of cancer, highly developed technical and analytical skills, an appreciation for the value of the interdisciplinary, collaborative research, and a commitment to pursuing cancer-focused studies. The training program has four key elements: 1) All trainees engage in cancer research projects under the direct supervision of the faculty. 2) All trainees participate in a specialized curriculum that includes two cancer-focused didactic courses, mentored attendance at a clinical Tumor Board, a course on scientific integrity, and regularly scheduled Journal Clubs. 3) All trainees obtain frequent feedback from faculty through an individual advising mechanism. 4) All trainees and mentors meet regularly to attend a Cancer Biology Journal Club, the Huntsman Cancer Institute Seminar Series, and an Annual Retreat. A strength of the MCRTP is the collaboration of physicians and basic scientists. The training faculty is comprised of 55 clinical and laboratory based investigators, all of whom have extramural funding for their research and are engaged in cancer related projects. Predoctoral trainees are selected from highly qualified, advanced graduate students. Postdoctoral trainees are selected from a large pool of both MDs and PhDs who seek focused training in cancer research. We will continue to support two predoctoral and eight postdoctoral trainees for two year terms. An Executive Committee appoints the trainees and conducts regular reviews of their progress. Our MCRTP trainees are integrated into a highly interactive, interdisciplinary community of researchers committed to understanding cancer biology and translating that information into more effective strategies for diagnosis and treatment.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA093247-10
Application #
8116068
Study Section
Subcommittee G - Education (NCI)
Program Officer
Damico, Mark W
Project Start
2002-02-19
Project End
2013-07-31
Budget Start
2011-08-01
Budget End
2013-07-31
Support Year
10
Fiscal Year
2011
Total Cost
$511,055
Indirect Cost

  Institution

Name
University of Utah
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112

  Publications

Woods, Ryan D; O'Shea, Valerie L; Chu, Aurea et al. (2016) Structure and stereochemistry of the base excision repair glycosylase MutY reveal a mechanism similar to retaining glycosidases. Nucleic Acids Res 44:801-10
Wagle, M; Eiring, A M; Wongchenko, M et al. (2016) A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Leukemia 30:1493-501
Jimenez, Laura; Wang, Jindong; Morrison, Monique A et al. (2016) Phenotypic chemical screening using a zebrafish neural crest EMT reporter identifies retinoic acid as an inhibitor of epithelial morphogenesis. Dis Model Mech 9:389-400
Piccolo, Stephen R; Hoffman, Laura M; Conner, Thomas et al. (2016) Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility. Mol Syst Biol 12:860
Khorashad, J S; Tantravahi, S K; Yan, D et al. (2016) Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy. Leukemia 30:2275-2279
Khorashad, Jamshid S; Eiring, Anna M; Mason, Clinton C et al. (2015) shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. Blood 125:1772-81
Piccolo, Stephen R; Andrulis, Irene L; Cohen, Adam L et al. (2015) Gene-expression patterns in peripheral blood classify familial breast cancer susceptibility. BMC Med Genomics 8:72
Eiring, Anna M; Page, Brent D G; Kraft, Ira L et al. (2015) Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia 29:586-597
Pomicter, Anthony D; Eiring, Anna M; Senina, Anna V et al. (2015) Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. Exp Hematol 43:537-45.e1-11
Eiring, A M; Khorashad, J S; Anderson, D J et al. (2015) ?-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Leukemia 29:2328-37

Showing the most recent 10 out of 64 publications